UNSPSC 51101660: Forminitrazole

This classification denotes an antiprotozoal agent with the molecular formula C4H3N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GTW8DB3OVN, chemically known as formamide, n- (5-nitro-2-thiazolyl)- but generally known as forminitrazole, which bears US NIH Compound Identifier 219073. European Medicines Agency schedules Forminitrazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07786MIG.

UNSPSC 51101660 Forminitrazole, a Commodity code, does not align with the state and local procurement opportunities tagged under it. The recent solicitations in this code span naloxone and drug deactivation systems, pharmacy benefit program direct-to-manufacturer contracting, general medical and first aid supplies for emergency responders, and generic multi-source pharmaceuticals and OTC products — none of which are forminitrazole, an antifungal pharmaceutical with limited state and local procurement presence. The code shows little relevant recent activity, and the tagged opportunities appear to reflect broader state and local health-sector purchasing classified under an incorrect or overly broad taxonomy entry rather than demand for the specific active pharmaceutical ingredient named in the code.

The issuing bodies include a county health department (Seminole County, Florida), a state health commission (Texas Health and Human Services Commission), a municipal fire department (City of Tampa), and a multi-state cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local jurisdictions in Minnesota and Oregon). Geographic activity spans Florida, Texas, and the Upper Midwest, with cooperative purchasing extending across multiple states. Recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems due July 26, 2023; Texas HHS's April 2026 RFI on direct-to-manufacturer prescription programs; the City of Tampa's March 2026 IFB for medical and first aid supplies estimated at $700,000 and designated for Small Local Business Enterprise set-aside with a 5 percent bid discount; and MMCAP's RFP for generic pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Business development professionals should verify their actual product scope against the code classification before pursuing opportunities tagged under this entry.